Food and Drug Administration: New standards to ensure the quality of complex medicines
The Saudi Food and Drug Authority (SFDA) has released a draft of updated regulatory requirements aimed primarily at controlling the quality of complex medicines intended for human use, known in scientific and medical circles as "synthetic peptides." This strategic step is part of the SFDA's ongoing efforts to promote public health. The draft has been made available to the public to gather feedback and suggestions from specialists and stakeholders for further development before its official approval. These medicines are defined as potent and sensitive pharmaceutical compounds that, in terms of size and chemical structure, occupy a delicate position between small drug molecules and large proteins, thus requiring exceptional standards for their handling.
Historical development of drug control in the Kingdom
Over the past decades, the healthcare sector in Saudi Arabia has undergone radical transformations, particularly in the area of drug regulation. The Saudi Food and Drug Authority (SFDA) was established as the overarching body responsible for ensuring the safety and efficacy of food, drugs, and medical devices. With the rapid advancements in biotechnology and the pharmaceutical industry globally, updating regulations to keep pace with these developments has become essential. These updates align with the objectives of Saudi Vision 2030, which places great emphasis on achieving pharmaceutical security and localizing advanced medical industries, thereby strengthening the Kingdom's position as a leading regional hub for healthcare and medical innovation.
Strategic dimensions for ensuring the quality and effectiveness of complex drugs
The importance of these regulations extends beyond the local level, encompassing broad regional and international implications. Establishing precise standards to ensure the quality of complex medications contributes to increased confidence in both locally manufactured and imported pharmaceutical products. Locally, these standards safeguard patients from any complications arising from drug impurities. Regionally, this step reinforces the Kingdom's leadership in developing medical legislation that may serve as a model for neighboring countries. Internationally, the alignment of the Authority's requirements with global standards facilitates trade and attracts foreign investment in the pharmaceutical industry.
Strict control over the manufacturing stages
The authority explained that this new regulation aims to provide specialized and precise oversight of the complex manufacturing processes involved in these amino acid chains, in order to protect public health. The new draft regulation excludes medicines derived from biological sources or recombinant DNA technologies, as well as radiopharmaceuticals, focusing entirely on quality standards and manufacturing processes. The authority emphasized that clinical aspects related to safety and efficacy fall outside the scope of this guide, which is exclusively dedicated to manufacturing processes and chemical control.
Regulations for manufacturers and development of generic drugs
In a related context, the new regulations require manufacturers to provide a detailed analytical description of the production and purification steps, while imposing strict controls on raw materials, reagents, and solvents used in manufacturing. The authority emphasized the necessity of using advanced analytical techniques to confirm the drug's structural integrity and precisely identify impurities, warning of the risks posed by impurities and drug aggregations, which could cause serious immune problems for patients. Regarding the development of generic drugs, the authority stipulated the submission of scientific studies demonstrating that the purity profile and impurity levels are identical to those of the chemically synthesized reference drug.
The authority also directed that extensive comparative analytical studies be conducted for drugs based on biological reference drugs, recommending the use of at least ten commercial batches to ensure the reliability and accuracy of the results. The Saudi Food and Drug Authority clarified that the current document is subject to revision based on feedback and suggestions received from the public and specialists, and cannot be considered a binding guide at this time. It added that the date for the mandatory implementation of these standards will be announced later, once the final version has been reviewed and approved, thus giving companies sufficient time to adapt to the new requirements.
